• Reported GAAP EPS of -$0.61 down -405.00% YoY • Reported revenue of $120.99M up 26.50% YoY
Bullish
GeneDx achieved significant revenue and gross profit growth in 2025, driven by increased exome and genome test volumes and strategic acquisition of Fabric Genomics' AI platform, enhancing its market position.
Bearish
GeneDx faces risks from evolving FDA oversight of LDTs, a material weakness in internal controls, and reliance on limited suppliers, which could lead to compliance delays, financial misstatements, and operational disruptions.